Miracor Medical Systems GmbH, a Vienna, Austria-based company that is commercializing a technology for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients, has received $3.5m (approximately €2.6m) in the form of a research grant and loan from the Austrian Research Promotion Agency.
The company intends to use the funding primarily to commence the pivotal clinical trial—RAMSES—of its PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system.
The RAMSES trial is designed to understand how PICSO can help acute coronary syndrome patients with large anterior infarcts having ECG changes with poor microcirculation after revascularization.
Led by CEO Jon H. Hoem, Miracor aims to establish PICSO as the standard of care for heart attack patients, thereby improving their quality of life. The system is CE-marked and can be used during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndromes to intermittently increase the pressure in the coronary venous system.
The technology is for investigational use only in the United States at this time.